The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since ...
For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarterit ...
None ...
With Novo Nordisk’s blockbuster drugs Wegovy and Ozempic back in stock, copycat versions of semaglutide are no longer allowed ...
People with a high body weight living in England can now access subsidized weight-loss drugs to treat their obesity. This ...
The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...
Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s ...
Makers of copycat versions of Novo Nordisk's (NVO) weight-loss drug semaglutide, also known as Ozempic and Wegovy, are suing ...
The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can ...
People taking the weight-loss drug semaglutide could be at a slightly increased risk for a potentially blinding eye condition ...